Lipid nanocapsules enhance the transdermal delivery of drugs regardless of their physico-chemical properties
[Display omitted] •Lipid nanocapsules (LNCs) were tailored for indomethacin, diclofenac or caffeine dermal and/or transdermal delivery.•LNCs are able to encapsulate indomethacin and diclofenac with greater than 98 % efficiency. Caffeine is not encapsulated inside the lipid core.•FTIR confirmed the i...
Gespeichert in:
Veröffentlicht in: | International journal of pharmaceutics 2022-11, Vol.628, p.122264-122264, Article 122264 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | [Display omitted]
•Lipid nanocapsules (LNCs) were tailored for indomethacin, diclofenac or caffeine dermal and/or transdermal delivery.•LNCs are able to encapsulate indomethacin and diclofenac with greater than 98 % efficiency. Caffeine is not encapsulated inside the lipid core.•FTIR confirmed the incorporation (or lack thereof) of the respective drug in lipid nanoparticles.•Ex vivo topical application of all studied drugs in LNCs is more effective than application of other conventional formulations.
The transdermal application of actives offers numerous advantages over other conventional routes. Namely, a stable level of drugs in the bloodstream and reduced side effects are the argument for topical administration. Unfortunately, the exceptional skin barrier and unsuitable physico-chemical properties of drugs are the limiting factors for the transdermal passage. It is possible to overcome this by incorporating the drug into nano-carriers to enhance its permeation through the skin barrier. For this purpose, we prepared lipid nanocapsules (LNCs) to modulate skin passage of three pharmaceutically important drugs – indomethacin (IND), diclofenac sodium (DF) and caffeine (CF). We present a stable system prepared by the phase inversion temperature method with particle size under 100 nm and PDI |
---|---|
ISSN: | 0378-5173 1873-3476 |
DOI: | 10.1016/j.ijpharm.2022.122264 |